The latest advances in the known genetics of neuroendocrine tumors such as SUCLG2 (succinyl-CoA ligase ß Subunit G2, an oxygen-sensing domain in hypoxia inducible factor 2) and IDH2 (isocitrate dehydrogenase 2) were recently reported (Lang et al., 2021; Hadrava Vanova et al., 2022). This evidence concerns the gene SUCLG2 and neuroendocrine neoplasm.